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Objective The aim of this study was to assess whether the
CYP2C9*2 and/or *3 variants might modify the risk for
NSAID-related upper gastrointestinal bleeding (UGIB) in
NSAID users.
Patients and methods We conducted a multicenter,
case–control study in which cases were patients aged more
than 18 years with a diagnosis of UGIB, and controls were
matched (1 : 3) by sex, age, date of admission, and hospital.
Exposure was defined as the mean number of defined daily
doses (DDDs) of NSAIDs metabolized by CYP2C9 in the
week preceding the index date. Three DDD categories were
defined (0, ≤ 0.5, and > 0.5). Exposure was constructed
taking both NSAID use and CYP2C9 polymorphisms into
account. Patients of non-European origin were excluded
from the analysis.
Results A total of 577 cases and 1343 controls were finally
included in the analysis: 103 cases and 89 controls
consumed NSAIDs metabolized by CYP2C9, and 88 cases
and 177 controls were CYP2C9*3 carriers. The adjusted
odds ratios (aORs) of UGIB associated with the CYP2C9*2
and wild-type alleles proved to be similar [OR= 8.79
(4.50–17.17) and 10.15 (2.92–35.35), respectively] and lower
than those of the CYP2C9*3 allele [aOR= 18.07
(6.34–51.53)] for consumers taking more than 0.5 DDDs of
NSAIDs metabolized by CYP2C9. Grouping genotypes into
carriers and noncarriers of the CYP2C9*3 variant resulted in
aORs of 16.92 (4.96–57.59) for carriers and 9.72 (4.55–20.76)
for noncarriers, where DDDs were greater than 0.5.
Conclusion The presence of the CYP2C9*3 variant
increases the risk for UGIB associated with NSAID for
DDDs greater than 0.5. The presence of the CYP2C9*2 allele
shows no such effect. Pharmacogenetics and Genomics
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Introduction
Upper gastrointestinal bleeding (UGIB) related to
NSAIDs is one of the most frequent and severe adverse
drug reactions (ADRs) [1–4]. This ADR has been
observed to have a very important idiosyncratic compo-
nent, which might be associated with some variants of the
gene that codes for enzyme CYP2C9 (the main meta-
bolizer of NSAIDs) [5–7]. This gene has two variants that
have functional consequences on enzyme activity and are
quite specific in populations of European origin, with
estimated prevalences of around 14% for CYP2C9*2
and 8% for CYP2C9*3 [8–10]. These variants – and
CYP2C9*3 in particular – can decrease the metabolism of
many NSAIDs [11,12]. Accordingly, carriers of these
variants could suffer a relative overdose, which would
increase their risk for UGIB, given the latter’s dose-
dependent nature [4,8]. Furthermore, the cost of deter-
mining these single-nucleotide polymorphisms (SNPs)
has been greatly reduced, which would ease their clinical
use for the purposes of preventing this ADR.
To date, six different studies have assessed the role of
the CYP2C9*2 and CYP2C9*3 variants in the risk for
NSAID-related UGIB [13–18] but their results have
been inconsistent [19]. Accordingly, this paper reports
the first full case–control study conducted with the aim of
ascertaining whether the presence of the CYP2C9*2 and/
or *3 variants might modify the risk for NSAID-related
UGIB, depending on the NSAID dosage consumed.
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Patients and methods
Study settings and design
An incident case–control study was implemented at hospi-
tals in four cities in northern Spain (Santiago de Compostela,
Valladolid, Galdakao, and Barcelona) and one in northern
Italy (Verona). Patients were recruited from January 2004
through November 2007. Informed consent was obtained
from all eligible patients, and the study was approved by the
ethics committee of each participant hospital.
Definition of cases and controls
Cases were defined as any person over 18 years of age
who met one of two conditions: (i) admitted to hospital
with a primary diagnosis of UGIB (hematemesis, vomitus
of red blood or ‘coffee-grounds’ material; melena; and/or
hematochezia) and shown by endoscopy to present with
acute lesions of the gastric mucosa or erosive duodenitis;
or (ii) having no clinical symptomatology of UGIB but
having undergone an endoscopy within 48 h of admission
in which signs of recent bleeding were evident.
Controls were recruited from the same hospitals as cases.
Both in Spain and Italy, hospitals have a defined geo-
graphical area of influence, and thus individuals living in a
particular area are allocated to a specific hospital. As geo-
graphical origin may be associated with the likelihood not
only of exposure but even of the prevalence of the poly-
morphisms studied, recruiting cases and controls from the
same source population prevents possible selection biases
[20]. Three controls were selected for each case and
matched by hospital, sex, age (± 5 years), and date of
admission (± 3 months). To prevent the selection of con-
trols from being associated with overestimation of expo-
sure to NSAIDs, controls were recruited from among
patients in the preoperative unit who were about to
undergo minor surgery for nonpainful clinical processes
unassociated with NSAID use (e.g. cataracts, prostate
adenoma, septoplasty, or lipoma removal).
The main exclusion criterion for cases and controls was
history of cancer, coagulopathy, Mallory–Weiss syn-
drome, or esophageal varices (Fig. 1). Individuals who
were not resident in the study area or had no reliable
interview data were also excluded. All exclusion criteria
considered are set out more fully in Fig. 1.
Clinical data collection
A comprehensive interview was conducted with both
cases and controls by trained health personnel, using a
questionnaire purpose-designed to collect sociodemo-
graphic information on patients, their personal clinical
history, toxic habits, grounds for admission, underlying
symptomatology (cases only), reason for the surgery for
which they had been scheduled (controls only), previous
episodes of gastric diseases, and exposure to drugs.
Four complementary strategies were pursued to obtain
the most complete pharmacologic anamnesis possible:
(i) participants were asked direct questions, including
about daily dose and indication, about any drugs (as well
as over-the-counter ones) that they had taken during the
preceding 2 months; (ii) they were also asked about fre-
quent symptoms for which NSAIDs are indicated, and
the treatments used to mitigate such symptoms; (iii) for
ease of recall, participants were shown prompt cards of
the most popular NSAIDs in each of the study areas; and
(iv) when a participant failed to remember any of the data
requested, either the interview was repeated at a later
date or, if the patient had been discharged, he/she was
contacted by telephone.
We defined the index date on the basis of patients’
clinical history but blind to their drug use: for cases, this
was the date of appearance of hematemesis, coffee-
ground vomitus, melena, or bloody stools (with hemor-
rhoids being ruled out); and for controls the index date
was deemed to be the date of interview. In line with
other studies that have analyzed the relationship
between exposure to NSAIDs and risk for UGIB [21,22],
we considered a 7-day etiologic window dating from the
index date.
Helicobacter pylori determination
Presence of anti-H. pylori IgG antibodies was determined
in the plasma of participants using a commercial ELISA
kit [23]. The serologic techniques used for H. pylori
determination are not affected by the presence of UGIB or
use of proton pump inhibitors (PPIs) [24]. To avoid false
positives due to old infections, we asked patients whether
they had received treatment for H. pylori infection.
Single-nucleotide polymorphism genotyping
Two different methods were used for genotyping parti-
cipants’ CYP2C9*2 and CYP2C9*3 variants: SNaPshot
technology and TaqMan Drug Metabolism Genotyping
Assays (Foster City, California, USA). Concordance
between the two methods was 100% [8]. All determina-
tions were masked as regards patients’ case or control
status and exposure to NSAIDs.
Definition of variables
An NSAID consumer was defined as any person shown
by pharmacologic anamnesis to have consumed some
medication belonging to this therapeutic group in the
week preceding the index date. Because of the low
prevalence of exposure to every single NSAID, it was not
possible to detect the interaction between each NSAID
and the CYP2C9 polymorphisms studied. Hence, to
obtain sufficient statistical power, the NSAIDs had to be
grouped. To this end, all NSAIDs that relied on the
above enzyme for at least 50% of their biotransformation
were considered: according to the literature, these were
celecoxib, diclofenac, ibuprofen, naproxen, aceclofenac,
indomethacin, lornoxicam, and piroxicam [9]. Finally, to
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perform an analysis of the NSAID dose effect, we cal-
culated the defined daily dose (DDD) and, as the amount
of no specific NSAID is comparable to that of another,
the DDD was then taken as reference. The DDD is the
average adult maintenance dose used for the main indi-
cation [25], and, in view of the fact that the main indi-
cation for the use of NSAIDs is the same, we used the
proportion of any given participant’s DDDs that
corresponded to NSAIDs metabolized by CYP2C9 as an
approximation of his/her level of exposure. Thus, the
dose–response effect was evaluated using three cate-
gories: (i) NSAID nonusers; (ii) NSAID users of 0.5
DDD or less; and (iii) NSAID users of over 0.5 DDD.
Acetylsalicylic acid was deemed to be an antiplatelet
agent when pharmacologic anamnesis showed that a
patient had taken it for a heart complaint.
Fig. 1
2750 cases∗ 1572 controls∗
577 cases 1343 controls
Primary exclusions:
Age < 18 (31)
Excludable endoscopic diagnosis (1213)
History of disease (121)
Intrahospital UGIB∗∗ (89)
UGIB without endoscopic or surgical diagnosis
     from admission to discharge (121)
Nasogastric or percutaneous tube carrier (75)
Less than 3 months' residence in study area (42) 
Admission time < 24 h (208)
Admission not due to UGIB (154)
Other (93)         
Exclusions:
Refused to sign informed consent form (45)
Age < 18 (1)
History of disease (11)
Intrahospital UGIB (89)
Nasogastric or percutaneous tube carrier (2)
Less than 3 months' residence in study area (1)
Severe condition (1)
Psychological disorders (1)
Deaf or blind (3)
Refusal to answer or failure to complete the
    interview (80)
Impossible to conduct interview within the 15-
    day period preceding admission (60)
Other (13)             
Secondary exclusions:
Refusal to sign informed consent form (21)
Occurred at weekend or vacations period (57)
Death (11)
Endoscopy performed more than 48 h after
    admission (83)
Discharge from hospital or visit to healthcare
    facility in the 15 days prior to admission




Deaf or blind (1)
Lives in a residence or closed institution and
    does not know the drugs taken (7)
Refusal to answer or failure to complete the
    interview (12)
Impossible to conduct interview within the 15-
    day period preceding admission (6)




Non-White patients (15)   
Flow of participants through the study. Each patient may have been excluded for more than one criterion. UGIB, upper gastrointestinal bleeding.
*Subjects may have been excluded on the basis of more than one criterion. **It was considered upper gastrointestinal bleeding from 48 hours before
hospitalization.
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The main drugs that might be related to gastrointestinal
events were also taken into account – that is, PPIs,
antiplatelet agents, and oral anticoagulants. For alcohol,
caffeine, and tobacco use, mean daily consumption over
the 2 months preceding the interview date was
calculated.
Statistical analysis
Possible bias in the selection of controls was evaluated by
reference assessment of the Hardy–Weinberg equili-
brium in both variants [26–29], using the SNPassoc
Library of the R package (v2.12.2) [30]. Deviation from
the Hardy–Weinberg equilibrium in the control group
indicates the probability of genotyping errors, and
selection or other bias [31]. To eliminate the risk of
stratification bias, all non-White patients (i.e. of non-
European origin) were excluded from the analysis.
To assess the risk for bleeding, adjusted odds ratios
(aORs) and their 95% confidence intervals (CIs) were
estimated by generalized linear mixed models for
dependent binomial-type variables (case or control)
[32,33]. The analysis was performed with this method
instead of the typical logistic regression because of the
nature of the design (a multicenter, matched case–control
study). To establish the effect on individuals, it was thus
necessary to consider three types of strata: level 1,
patients; level 2, cases and matched controls; and level 3,
hospitals.
To construct the models, we first performed a bivariate
analysis, and then selected all independent variables
having a P-value lower than 0.2 for multivariate analysis.
Second, the variables so selected were then studied in a
multivariate analysis. The variables with the highest level
of statistical significance were successively eliminated,
provided that the coefficients of the principal variables of
exposure changed by no more than 10% [34] and
improved the Schwartz’s Bayesian Information Criterion
[35], until the most appropriate model had been
obtained. The reference category considered in interac-
tions between DDDs of NSAIDs and genotype or allele
was absence of exposure to NSAIDs and wild-type
genotype or wild-type allele [36]. The lmer function
was used for estimation of the models: it is implemented
in the lme4 library of the R package (v2.12.2) [33].
We also calculated the additive interaction [S (95% CI)]
as the rate between the combined effects of genetic
variants and NSAIDs, and the sum of these effects con-
sidered separately. S has been shown to be the most
reliable measure of additive interaction when adjusting
for confounding [37].
Results
Of the 4325 patients who were interviewed, 577 cases
and 1343 controls were finally included in the analysis
(Fig. 1). Table 1 shows the demographic and clinical
characteristics of cases and controls.
Table 1 Description of cases and controlsa
N (%)
Cases (n=577) Controls (n=1343) P-valueb
Demographic variables
Sex (men) 426 (73.8) 940 (70.0) 0.077
Age [mean (SD)] 62.77 (16.856) 63.45 (15.585) 0.376
Interview variables
Number of interviews conducted <0.001c
1 500 (86.7) 1278 (95.2)
≥2 77 (13.3) 65 (4.8)
Reliability of interview 0.020c
<5 29 (5.0) 36 (2.7)
5–7 67 (11.6) 158 (11.8)
7–9 252 (43.7) 564 (42.0)
≥9 229 (39.7) 585 (43.6)
Comorbidity
BMI [mean (SD)] 26.58 (4.351) 26.60 (4.01) 0.959
Diabetes 95 (16.5) 185 (13.8) 0.144
Cardiovascular disease 153 (27.0) 280 (21.0) 0.005c
Arterial hypertension 227 (39.4) 506 (38.0) 0.654
Elevated cholesterol 174 (30.5) 379 (28.5) 0.356
Positive Helicobacter
pylori
338 (91.4) 911 (80.6) <0.001c
Personal history of GI disorders <0.001c
None or dyspepsia 371 (64.6) 1147 (85.8)
Ulcer 81 (14.1) 105 (7.9)
Bleeding 122 (21.3) 85 (6.4)
Arthrosis 169 (30.8) 444 (35.3) 0.048c
Arthritis 63 (5.1) 34 (6.2) 0.270
Consumption of caffeine 486 (84.2) 1133 (84.4) 0.766
Smoking habit 0.056
Nonsmoker/ex-smoker 426 (73.8) 1043 (77.7)
Moderate 68 (11.8) 150 (11.2)
Heavy 83 (14.4) 150 (11.2)
Alcohol 0.056
Abstainer 468 (34.8) 196 (34.0)
Little 676 (50.3) 274 (47.5)
Moderate 175 (13.0) 86 (14.9)
Heavy 24 (1.8) 21 (3.6)
Comedication
NSAID –
DDD of NSAID=0 455 (78.9) 1229 (91.5)
0>DDDs of
NSAID≤0.50
66 (11.4) 65 (4.8)
DDDs of NSAID>0.50 56 (9.7) 49 (3.6)
Exposure to NSAID not
metabolized by
CYP2C9
186 (32.2) 209 (15.6) <0.001c
Exposure to PPIs 53 (9.2) 170 (12.7) 0.029c
Exposure to antiplatelets 116 (20.1) 186 (13.8) <0.001c
Exposure to
anticoagulants
43 (7.5) 63 (4.7) 0.011c
Exposure
NSAID metabolized by CYP2C9 <0.001c
DDD of NSAID=0 474 (82.1) 1254 (93.4)
0>DDDs of
NSAID≤0.50
54 (9.4) 55 (4.1)
DDDs of NSAID>0.50 49 (8.5) 34 (2.5)
CYP2C9 genotype 0.095
CYP2C9*1/*1 299 (59.4) 742 (59.6)
CYP2C9*1/*2 105 (20.9) 295 (23.7)
CYP2C9*2/*2 11 (2.2) 31 (2.5)
CYP2C9*1/*3 66 (13.1) 142 (11.4)
CYP2C9*2/*3 13 (2.6) 27 (2.2)
CYP2C9*3/*3 9 (1.8) 8 (0.6)
DDD, defined daily dose; GI, gastrointestinal; PPI, proton pump inhibitors.
aNon-European patients were excluded.
bThe P-value for this variable is polychotomous – that is, it is the joint P-value for
the entire variable.
cVariables included in the multivariate model.
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The CYP2C9 genotype was obtained in 91.0% of indivi-
duals. Table 2 shows the distribution of CYP2C9 geno-
type frequencies for cases and controls. Calculation of the
Hardy–Weinberg equilibrium showed that controls were
in equilibrium in terms of both the *2 (P= 0.745) and *3
variants (P= 0.538).
Risk for UGIB associated with each allele was also ana-
lyzed, taking the NSAID dose consumed into account
(Table 3). For DDDs of NSAID in excess of 0.5, risk for
UGIB was observed to be similar for the *2 and wild-type
variants [OR= 8.79 (4.50–17.17) and 10.15 (2.92–35.35),
respectively], and very much lower than that for the *3
variant [aOR= 18.07 (6.34–51.53)]. In view of these
results, patients were grouped into two categories: car-
riers and noncarriers of the *3 allele (Table 4). From
DDDs of 0.5 upward, risk for UGIB among carriers of
genotypes with the *3 variant was 16.92 (4.96–57.59;
P< 0.001) versus 9.72 (4.55–20.76; P< 0.001) among
carriers of genotypes with the *2 and/or wild-type
variants. Despite the absence of statistical significance,
this interaction might well be additive [S= 1.75
(0.40–7.69)]. All these models were adjusted for personal
history of gastrointestinal disorders, presence of H. pylori,
osteoarthritis, number of interviews conducted with each
patient, reliability of the interview, exposure to PPIs,
antiplatelet agents, oral anticoagulants, and NSAIDs not
metabolized by CYP2C9.
Lastly, when the number, site, and type of lesion (erosion
or ulcer) were analyzed (Table 5), it was observed that
NSAIDs consumers and carriers of CYP2C9*3 had more
lesions/patient (2.0) than did NSAID consumers (1.7) or
carriers of the *3 variant (1.7). It is noteworthy that 93.7%
(15/16) of NSAID consumer carriers of CYP2C9*3 pre-
sented with a duodenal ulcer versus 62.0% (314/506) of
the remaining cases (P< 0.05).
Discussion
In this full case–control study, we found that the pre-
sence of the CYP2C9*3 variant increases the risk for
UGIB associated with NSAID consumption; this occurs
among persons taking doses higher than that regarded as
half the average dose (>0.5 DDD). In view of the fact
















CYP2C9*1/*1 59.5 299 (59.4) 59.6 742 (59.6)
CYP2C9*1/*2 22.9 105 (20.1) 22.9 295 (23.7)
CYP2C9*2/*2 2.4 11 (2.2) 2.4 31 (2.5)
CYP2C9*1/*3 11.9 66 (13.1) 11.9 142 (11.4)
CYP2C9*3/*3 1.0 9 (1.8) 0.9 8 (0.6)
CYP2C9*2/*3 2.3 13 (2.6) 2.3 27 (2.2)








†P≤0.05 was deemed statistically significant.
Table 3 Risk for upper gastrointestinal bleeding associated with
each allele of CYP2C9
Adjusted ORa (95% CI) P-value
Allele CYP2C9*1
DDDs of NSAIDs=0 1.00 (ref) –
0<DDDs of NSAIDs≤0.50 3.19 (1.76–5.78) <0.001
DDDs of NSAIDs>0.50 8.79 (4.50–17.17) <0.001
Allele CYP2C9*2
DDDs of NSAIDs=0 1.05 (0.77–1.42) 0.776
0<DDDs of NSAIDs≤0.50 1.31 (0.36–4.71) 0.679
DDDs of NSAIDs>0.50 10.15 (2.92–35.35) <0.001
Allele CYP2C9*3
DDDs of NSAIDs=0 1.54 (1.04–2.26) 0.030
0<DDDs of NSAIDs≤0.50 2.61 (0.62–11.10) 0.193
DDDs of NSAIDs>0.50 18.07 (6.34–51.53) <0.001
CI, confidence interval; DDD, assumed average maintenance dose per day for a
drug used for its main indication in adults.
aORs adjusted for the following confounding variables: personal history of gas-
trointestinal disorders; presence of H. pylori; osteoarthritis; number of interviews
conducted with the patient; reliability of the interview; patients exposed to proton
pump inhibitors, antiplatelet agents, oral anticoagulants, and NSAIDs not metab-
olized by CYP2C9.
Table 4 Dose of NSAIDs metabolized by CYP2C9, genotypes
carrying the CYP2C9*3 variant, and related risk for upper
gastrointestinal bleeding
Genotype/NSAID dose (in DDDs) Adjusted ORa (95% CI) P-value
Genotypes without CYP2C9*3b
DDDs of NSAIDs=0 1.00 (ref) –
0<DDDs of NSAIDs≤0.5 3.22 (1.68–6.20) <0.001
DDDs of NSAIDs>0.5 9.72 (4.55–20.76) <0.001
Genotypes with CYP2C9*3c
DDDs of NSAIDs=0 1.37 (0.90–2.11) 0.140
0<DDDs of NSAIDs≤0.5 3.88 (0.85–17.81) 0.080
DDDs of NSAIDs>0.5 16.92 (4.96–57.59) <0.001
CI, confidence interval; DDD, assumed average maintenance dose per day for a
drug used for its main indication in adults.
aORs adjusted for the following confounding variables: personal history of gas-
trointestinal disorders; presence of Helicobacter pylori; osteoarthritis; number of
interviews conducted with the patient; reliability of the interview; patients exposed
to proton pump inhibitors, antiplatelet agents, oral anticoagulants, and NSAIDs
not metabolized by CYP2C9.
b*1/*1,*1/*2, or *2/*2.
c*1/*3,*3/*3, or *2/*3.
Table 5 Number and type of localization of lesions, by exposure to














Gastric 41 (39.8) 25 (28.4) 4 (25.0) 102 (25.4)
Duodenal 32 (31.1) 22 (25.0) 8 (50.0) 55 (13.7)
Ulcers
Gastric 55 (53.4) 39 (44.4) 5 (31.3) 125 (31.1)
Duodenal 56 (54.4) 59 (67.0) 15 (93.7) 199 (49.5)
Pyloric 8 (7.8) 0 0 13 (3.2)
Figures in brackets show the corresponding percentages.
Each patient may have more than one lesion.
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that NSAIDs are one of the most widely used treatment
groups worldwide [38], that ∼ 14% of the population of
European origin carries genotypes with the *3 variant
[8–10], and that genotyping costs are very low, our find-
ing could enable the risk for UGIB in this population to
be substantially reduced.
We observed that patients who consumed mean DDDs
of NSAIDs in excess of 0.5 and who carried the *3 allele
had a nearly two-fold increased risk of suffering from
UGIBs as compared with patients who consumed the
same dose but were noncarriers of this variant. In con-
trast, we found that the pattern of behavior of the *2
allele was very similar to that of the wild type, thereby
enabling patients to be grouped into carriers or non-
carriers of the *3 allele, and important differences to be
detected in CYP2C9-related risk of suffering from UGIB.
This finding is analogous to the results of studies
undertaken with other drugs that have a narrow thera-
peutic index and are also metabolized by CYP2C9, such
as warfarin [39], phenprocoumon [28], and phenytoin
[29], where the increased risk is higher for carriers of the
*3 allele. Our results are also in agreement with in-vitro
and in-vivo studies that report that, compared with
CYP2C9*2, CYP2C9*3 has a high impact on the clearance
of most NSAIDs [12].
This is the first study to our knowledge to analyze the
role of enzyme CYP2C9 in the risk for UGIB considering
NSAID dosage. We observed that at low doses the pre-
sence of the *3 allele did not increase the risk for UGIB
with respect to noncarriers but that from a DDD of 0.5
there was an important increase in risk among carriers of
the *3 allele. This finding is in agreement with (i) the
known dose-dependent nature of NSAID-induced gas-
trointestinal damage [4]; and (ii) the increase in plasma
NSAID levels among carriers of the *3 allele [5,9].
Accordingly, at low doses there would be no increase in
the risk for UGIB, regardless of the presence of the
variants studied. For medium and high doses, however,
the presence of the *3 variant plays a relevant role in the
increase in risk, whereas the *2 allele shows a similar risk
to the wild-type allele, probably because CYP2C9*3 has a
higher impact than CYP2C9*2 on the clearance of most
NSAIDs [12]. These results would indicate that the
presence of the *3 variant can be used as a UGIB risk
marker among consumers of NSAIDs metabolized
through this pathway.
Our study has a number of strengths and limitations. (i)
Its principal strength lies in the fact that it was the first
full case–control study to assess the present hypothesis.
Most of the previous studies [13–17] had an exposed-
only (or partial case–control) design [40], thus making it
impossible to analyze this interaction or effect modifier
because data on unexposed individuals were lacking [19].
Another earlier study [18] had a case-only design
but this design allows for multiplicative interactions;
nevertheless, additive interactions are far more common
in biology [41]. (ii) In contrast to the other full
case–control study [42], which did not take NSAID
exposure into account, we assessed whether CYP2C9
variants might modify the risk of the relationship
between NSAIDs and UGIB. (iii) A further strength is
the fact that the control group in our study fulfilled the
Hardy–Weinberg equilibrium, which was not the case in
other studies [13–16]. Lastly, another advantage of our
study is that stratification bias was controlled for [43,44]
by excluding non-Whites from the analysis.
The main limitation of our study pertains to the sample
size: despite it being the largest with respect to that of
other papers published to date on this topic [13–18], the
sample size used was not high enough to conduct an
analysis by genotype. However, our sample size was large
enough to analyze the effect of each allele. Another
possible limitation was our failure to determine the
CYP2C8 and CY2C19 polymorphisms. We nevertheless
feel that not having determined CYP2C8 does not affect
the study’s validity, as CYP2C8 plays a very marginal role
in the clearance of NSAIDs [12]: its partial metabolizing
role has only been described for the (R)-enantiomer of
ibuprofen [12], and in-vitro studies have shown this role
to be very marginal [45]. Furthermore, if its role were
indeed important, then an increased residual risk would
be observed in CYP2C9*2 carriers, because of its partial
binding disequilibrium with CYP2C9*3 [12]. In our
study, the risk associated with the *2 allele was found to
be very similar to that of the *1 allele, something that
would also support the negligible role played by CYP2C8
in NSAID clearance. With respect to CYP2C19, we
found no evidence to indicate that it might be associated
with NSAIDs-related UGIB. Moreover, there is no
description of it playing a relevant metabolizing role in
any NSAID [12]. Some direct association with risk for
UGIB has been found but this is in no way related to
NSAID use [42].
All in all, understanding that pharmacogenetics con-
tribute to variability in the NSAIDs dose–risk relation-
ship may help when it comes to choosing the NSAID and
the dosage that is safest and most effective. We found
that patients carrying the *3 variant experienced a higher
risk for NSAID-related UGIB. The use of CYP2C9 test-
ing could be a method for identifying such higher-risk
patients who are candidates for taking lower NSAID
doses or for using NSAIDs not metabolized by the
CYP2C9 enzyme. If our results are confirmed by other
studies and, bearing in mind (i) that NSAIDs are one of
the most widely used therapeutic groups, (ii) the elevated
incidence of NSAID-related UGIBs, and (iii) the current
low cost of SNP determination, these findings could have
significant implications for clinical practice and public
health.
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